3 April 2023 - In late March, the House Committee on Energy and Commerce advanced H.R. 485 - Protecting Health Care for All Patients Act - on a party line vote with Republicans favouring an amended version of the bill which aims to block the ability of entities in the public and private sectors to use comparative effectiveness research measures to assess the value of medications for patients.

H.R. 485 specifically seeks to prohibit the use of quality adjusted life years (QALYs) in all federal programs. This would represent an expansion from the current prohibition that only applies in a limited way to the Medicare program.

Read Forbes article